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Magid H AmerAbstract
Advancements in human genomics over the last two decades have shown that cancer is mediated by somatic
aberration in the host genome. This discovery has incited enthusiasm among cancer researchers; many now use
therapeutic approaches in genetic manipulation to improve cancer regression and find a potential cure for the
disease. Such gene therapy includes transferring genetic material into a host cell through viral (or bacterial) and
non-viral vectors, immunomodulation of tumor cells or the host immune system, and manipulation of the tumor
microenvironment, to reduce tumor vasculature or to increase tumor antigenicity for better recognition by the
host immune system. Overall, modest success has been achieved with relatively minimal side effects. Previous
approaches to cancer treatment, such as retrovirus integration into the host genome with the risk of mutagenesis
and second malignancies, immunogenicity against the virus and/or tumor, and resistance to treatment with disease
relapse, have markedly decreased with the new generation of viral and non-viral vectors. Several tumor-specific
antibodies and genetically modified immune cells and vaccines have been developed, yet few are presently
commercially available, while many others are still ongoing in clinical trials. It is anticipated that gene therapy will
play an important role in future cancer therapy as part of a multimodality treatment, in combination with, or
following other forms of cancer therapy, such as surgery, radiation and chemotherapy. The type and mode of gene
therapy will be determined based on an individual’s genomic constituents, as well as his or her tumor specifics,
genetics, and host immune status, to design a multimodality treatment that is unique to each individual’s specific
needs.
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Over the last two decades, cancer research and genomics
have experienced considerable advancements. In 2001,
two independent draft versions of the human genome
sequence and the concomitant identification of approxi-
mately 30,000 genes were published [1,2]. As expected,
this was followed by extensive research in molecular
genetics with advanced tools used to dissect gene func-
tion and explore the biological processes involved in
causing genetic aberration and malignant transformation
[3]. The recent proliferation of knowledge of cancer has
led to the development of novel therapeutic approaches
in cancer management, particularly gene therapy.Correspondence: magidamer@email.com
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unless otherwise stated.Gene therapy implies any procedure intended to treat
or alleviate a disease by genetically modifying the cell of
a patient [4]. The material to be transferred into patient
cells may be genes, gene segments, or oligonucleotides.
Gene transfer therapy can be conducted either as in vivo
or ex vivo approaches. In the in vivo approach, targeted
cells are approached directly, such as the intradermal in-
jection of a metastatic nodule, or intravesical therapy for
superficial bladder cancer. In the ex vivo approach, tar-
geted cells from a tumor are selected, then collected,
grown in culture media at a controlled microenviron-
ment, manipulated genetically by the insertion of a new
gene or protein (transgene) in the cell genome, then in-
troduced back into the host. The ex vivo approach is
much simpler to achieve as it is easier to manipulate tar-
get cells externally.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and replace non-functioning tumor suppressor genes were
barely successful. Subsequently, new approaches have been
developed to transfer genetic materials (transgenes) dir-
ectly into target cells aiming to transiently or permanently
change their phenotypes [5]. Target cells may be normal
cells, cancerous cells, immune mediated cells, or pluripo-
tent stem cells. Once the transgene enters a cancer cell, it
can then assists in its death or restore normal cellular
functions, whereas for normal cells, the transgene can
protect them from drug-induced toxicities, or activate an
immune cell to get rid of the cancer cell. Gene and
vector-based molecular therapies for cancer comprise a
wide range of treatment modalities to modify cancer cells,
normal cells, and/or a tumor microenvironment [6].
History
The history of cancer therapy dates back to the eighteenth
century, when surgery was the primary treatment for early
stages of cancer, and patients suffered from frequent re-
lapses [7]. Once the disease spread, patients were treated
with herbal medications, castor oil, or arsenic. In 1895, ra-
diation therapy was discovered, but resulted in few cures
[8]. At that time, several cases of spontaneous cancer re-
gression following bacterial infection were reported [9]. In
1868 a patient with soft tissue sarcoma went into remis-
sion following an erysipelas infection, but this regression
lasted for a short duration [9]. In 1943, nitrogen mustard
was used in the management of patients with lymphoma
[10], and in 1948 folic acid antagonists led to transient re-
mission in childhood leukemia [11]. Since then, there has
been a dramatic advancement in chemotherapy treatment
for cancer [7]. Viruses were also found to be effective in
controlling malignancies in animal models, and subse-
quently in humans in 1956 [12]. Adenoviruses in particu-
lar have been studied more intensively in humans, with
the subsequent development of gene therapy [13]. In
1987, immunotherapy was introduced in the management
of cancer patients with subsequent FDA approval of ritux-
imab antibodies in the treatment of patients with lymph-
oma (1997) [14].
The first FDA-approved gene therapy experiment in
the United States occurred in 1990 for a patient with se-
vere combined immunodeficiency disorder [15]. Since
then, many clinical trials have been conducted for patients
with cancer, using different approaches in gene therapy,
with successful results reported in patients with chronic
lymphocytic leukemia, acute lymphocytic leukemia, brain
tumors, as well as others. Several commercially approved
medications for gene therapy were released, including
ONYX-15 (Onyx Pharmaceuticals) for refractory head and
neck cancer (2005) [16]; human papilloma virus vaccine
(Gardasil) (Merck Sharp & Dohme) for the prevention
of cancer cervix (2006) [17]; and modified dendriticcells, sipuleucel-T (Provenge) (Dendreon Corporation,
Seattle, WA), for minimally symptomatic, castration-
resistant metastatic prostate cancer (2010) [18].
Methods of gene therapy
Gene therapy implies an approach that aims to modify,
delete, or replace abnormal gene(s) at a target cell. Such
target cells may be malignant primary or metastatic nod-
ules, circulating tumor cells or dormant stem cells, and
specific cells such as T-cell lymphocytes or dendritic cells.
With the presence of over 20,000 active genes in human
cells, exposed to numerous factors whether hereditary,
environmental, infectious or spontaneous, unlimited
possibilities for gene mutation, aberration, dysfunction
or deletion have been expected, leading to clinical presen-
tation of various medical disorders, including cancer.
Furthermore, genomics of cancer evolve between pri-
mary and metastases. For example, estrogen receptor gene
(ESR J) mutations in breast cancer were found in propor-
tion of metastases but not in primary tumors [19,20].
Whole-exome sequencing of metastatic samples reported
among the top 17 mutated genes, only five were mutated
in primary tumors [21]. The evolution from minority
clone to lethal metastases follows branched evolution.
Thus, tumors with high a level of intratumor heterogeni-
city and genomic instability could be more likely to escape
from targeted therapies such as gene therapy, unless such
a branched evolution is taken into consideration. Hence,
gene therapy is somewhat difficult to achieve, with limited
success. Presently, most approaches are for monogenic
gene therapy, tackling one or more critical gene defects.
Selection of the appropriate mode of gene therapy is based
on the assessment of the immune status, and determin-
ation of the molecular nature of a patient’s disease. With
the recent increases in knowledge of molecular biology of
various medical disorders, a more advanced and compre-
hensive gene therapy approach will ultimately become
available, with anticipated improved results.
Gene transfer delivery system
Several methods have been developed to facilitate the
entry of genetic materials (transgenes) into target cells,
using various vectors. They are broadly divided into two
major categories: viral (or bacterial) and non-viral vec-
tors [Table 1]. Viruses usually bind to target cells and
introduce their genetic materials into the host cell as
part of their replication process. As they enter target cells,
they can carry a load of other genetic material called
“transgenes”. For non-viral vectors, different approaches
have been utilized, using physical, chemical, as well as
other modes of genetic transfer. Transferring genetic ma-
terial directly into cells is referred to as “transfection”,
while moving them into cells carried by a viral or bacterial
vector is termed “transduction”. Non-viral approaches
Table 1 Gene transfer and immunomodulation in cancer therapy





Non-Viral Electroporation, nanoparticles, hydrodynamics, cationic liposomes, transposon,
synthetic viruses
18,1,0
Bacterial Escherichia coli, Salmonella, Clostridium, Listeria, CEQ508 6,0,0
Viruses
ssDNA viruses Adeno-Associated: Parvovirus
dsDNA viruses Adenoviruses: Ad5-D24, CG870, Ad5-CD/TKrep, Recombinant H103, Gutless
adenovirus, OBP-301
ONYX-015 11,3,0
dsDNA viruses Herpetic viruses: Herpes simplex-1, TVEC 42,10,0
ssRNA viruses Lentiviruses: HIV-1, HIV-2, Simian IV, Feline IV. 8,2,0
dsRNA viruses Reoviruses 9,1,0
Immunomodulation
Active immunotherapy 41,3,0
Single Tumor cell surface antigen vaccine
Antigen-specific plasmid-based vaccine: PSA, HER/2, Modified CEA vaccine.
Tumor cells, irradiated as vaccine
Genetically modified tumor cell vaccine: Using Poxvirus, Vaccinia virus,
Recombinant fowlpox virus, Combination (TRICOM) (Prostvac-VF vaccine).
Passive immunotherapy 219,29,2
Antibodies against: Rituximab
CD20 Protein on lymphoma cells Rituximab
HER/2 receptor protein in breast cancer Trastuzumab
CD52 Protein on CLL Alemtuzumab
CD20 Protein on lymphoma cells Ibritumomab
CD20 Protein on lymphoma cells Tositumomab
EGFR Receptor on squamous CA Cetuximab
EGFR Receptor on colorectal CA Panitumumab
CD20 Protein on CLL Ofatumumab
CD30 Protein on Hodgkin lymphoma cells Brentuximab
HER/2 receptor protein in breast cancer Pertuzumab
HER/2 receptor protein in breast cancer Ado-Trastuzumab
CD20 Protein on CLL Obinutzumab
Adoptive immunotherapy 15,1,0
Autologous activated T- lymphocytes Sipuleucel-T
Genetically modified activated T-lymphocytes
Chimeric antigen receptor integrated T-lymphocytes
Activated dendritic cells
Genetically modified dendritic cells
Immune enhancement 11,1,0
Antibodies blocking CTLA-4 Inhibitors for malignant melanoma. Ipilimumab
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Table 1 Gene transfer and immunomodulation in cancer therapy (Continued)
Microenvironment modification
Impact on vasculature Humanized monoclonal antibodies against VEGFR-A Bevacizumab
Anti-angiogenic genes (against VEGFR-A): Endostatin, Angiostatin 22,4,0
Abbreviations: CA Cancer; CEA carcinoembryonic antigen; CLL chronic lymphocytic leukemia; ds double stranded; CTLA-4 cytostatic T-lymphocyte antigen 4; DNA
deoxy nucleic acid; EGFR epidermal growth factor receptor; FDA Food and Drug Administration in United States; HER/2 human epidermal growth factor receptor-2;
HIV human immunodeficiency virus; PSA prostatic acid phosphatase antigen; RNA ribonucleic acid; ss single stranded; VEGF-A vascular endothelial growth factor
A receptor.
*Commercially approved medications by FDA US as of July 1, 2014. ONYX-015 was previously approved by FDA China.
**Clinical trials: Number of active clinical trials on gene therapy for cancer (Phases-II, -III, and –IV) as of July 1, 2014 (www.clinicaltrials.gov).
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have a lower transfection efficiency compared to viral vec-
tors [22].Physical mediated gene transfer
DNA genetic material that is coated with nanoparticles
from gold or other minerals, and with their kinetic en-
ergy supplemented by compressed air or fluid (gene
gun), or using ultrasound, can force the genetic material
into the target cell, followed by the release of DNA into
its nucleus. They are best suited for gene delivery into
tissue or in case of gene vaccination [23].
The electroporation gene therapy approach aims to
achieve cellular membrane disruption with high-voltage
electrical pulses, resulting in the formation of nanopores
through which naked DNA, foreign genetic materials, and
even chemotherapeutic agents can enter cells [23,24]. This
approach is best suited for plasmid DNA-based gene
transfer therapy with the advantage of effectiveness in a
vast array of cell types, ease of its administration, lack of
genome integration with the risk of malignancy, as well
as the low potential for unwanted immunogenicity [22].
Electroporation is presently being tested in several clinical
trials, especially on patients with malignant melanoma,
prostate cancer, colorectal cancer, and leukemia [22].Chemical mediated gene transfer
Cationic liposomes are microscopic vesicles of synthetic
phospholipids and cholesterol that can enter into cells
by endocytosis [25], with the capability of carrying a var-
iety of molecules such as drugs, nucleotides, proteins,
plasmids and large genes [23]. Their advantage is selectiv-
ity to endothelial cells, a relatively high rate of gene trans-
fer efficiency, a broad application as carriers for many
genes, and the lack of severe side effects [26]. When com-
bined with small interfering RNA (siRNA), cationic lipo-
somes may lead to the inhibition of tumor proliferation,
inducement of apoptosis, and enhancement of radiosensi-
tivity to tumor cells [27].
Synthetic viruses have been developed to exploit the
efficiency of viral vectors and the advantage of liposomes
[28]. Once they enter the target cell, DNA is releasedfrom the endosome. This method has shown promising
results in preclinical studies [29-32]. Transposons can
also transport genetic material inside the cell as well as
into the nucleus [33].Bacterial mediated gene transfer
Some bacteria have the capability of specifically targeting
tumor cells, leading to RNA interference (RNAi) and gene
silencing with blockage of RNA functions, including cellu-
lar metabolism and protein synthesis. Examples include
Escherichia coli, Salmonella typhimurium, Clostridium,
and Listeria [34]. Bacterial vectors can deliver pro-drug-
converting enzymes and cytotoxic agents into tumor cells,
and can mediate the host immune response. They can be
engineered to carry magnetic or fluorescent material to
enhance the utility of diagnostic approaches in tumor
localization, such as with magnetic resonance imaging
(MRI) [35], and even in the development of cancer vac-
cines [36]. However, the outcome has been far less pro-
nounced compared to other RNA interference silencing
techniques. Overall, genetically engineered bacteria acting
as vectors for RNA interference are relatively safe, effective,
practical and cheaper to manufacture compared to viral
vectors. They selectively colonize and grow within the
tumor. They can also be administered orally, hence their
use in the management of gastrointestinal disorders [34].Viral mediated gene transfer
Viruses are small particles that contain either ribonucleic
acid (RNA) or deoxyribonucleic acid (DNA), and may be
single-stranded (ss) or double-stranded (ds). The viral
structure consists of a genome surrounded by a protective
protein coat (viral capsid) which helps the virus attach to
host cell receptors, and prevents viral destruction by cell
nuclease enzymes. Some viruses may also have a lipid bi-
layer envelope derived from the host cell’s membrane,
and an outer layer of viral envelope made of glycopro-
tein. A complete viral particle (virion) by itself is unable
to replicate. For propagation, the virus needs to insert its
genetic material into a host cell, in order to acquire meta-
bolic and biosynthetic products for viral transcription
and replication.
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As they enter the cell, they can carry genetic material for
delivery into a target cell’s cytoplasm, and subsequently
into the nucleus. In monogenic gene therapy, virus vectors
can carry a load of 2–10 kb of relevant genes. In high
complex gene therapy, other supporting molecules can
also be added, such as immune-stimulatory molecules to
the virus’s DNA for subsequent release during viral repli-
cation. The advantage of viral vectors in gene therapy is
the ease of purification into high titers, and prolonged
gene expression with minimal side effects. Retroviruses in-
cluding lentiviruses can integrate themselves into host cell
genome at the nucleus, while adenoviruses and adeno-
associated viruses predominantly persist as extrachromo-
somal episomes [24,37].
RNA viruses comprise about 70% of all viruses, and vary
greatly in genomic structures. They usually have a higher
mutation rate with increased adaptation to attack different
host cells. Single-stranded RNA viruses may have a viral
reverse transcriptase enzyme in their genome, which helps
in genetic transcription of the viral genome inside the host
nucleus, into double-stranded pro-viral DNA. With viral
integrase, the pro-viral DNA then integrates with the host
DNA making the subsequent transcription of other parts
of the virus possible, in order to give rise to a new retro-
virus progeny. The proteins of the mature virion are then
rearranged to form the new viral particles. Viral particles
subsequently destroy the host cell, and release mature vi-
ruses to attack neighboring cells. Double-stranded DNA
viruses enter the host cells by endocytosis through inter-
action between the virus and cell receptor. The virus then
enters the nucleus through nuclear pores once they escape
cellular endosome [38,39]. The virus subsequently releases
two gene products which bind to the retinoblastoma and
p53 tumor suppressor genes, thus allowing viral replica-
tion. New viruses then cause cell lysis and the released vi-
ruses spread to attack neighboring cells [38].
Adenoviruses
Adenoviruses are double-stranded DNA viruses that
usually cause mild respiratory, digestive and ocular in-
fection in humans. In gene therapy, modified versions
of adenovirus and adeno-associated viral vectors have
been designed. Compared to wild-type, they are more
potent in infecting cells, both dividing and non-
dividing, replicate exclusively in tumor cells [40], and
selectively target certain cellular receptors or molecu-
lar defects. They pose a very high transduction
efficiency, which may approach 100%, with fewer
tendencies for viral shedding and latent infection.
They can easily be produced commercially in large
quantities, and are capable of carrying pro-drug genes
as well as others [41]. However, they have several
pitfalls, including the tendency to develop geneticinstability of carried genes. Subsequent chromosomal
aberration may lead to the development of lympho-
proliferative disorders. As nearly half of all humans
have been exposed to these viruses during their life-
time, with the generation of neutralizing antibodies,
they may lead to high immunogenicity, with shorter dur-
ation of adenoviral-mediated transgene expression
[42].
Modified oncolytic adenoviruses are presently tested
in different clinical trials, especially in patients with as-
trocytoma of the brain, in combination with radiation
and/or temozolomide chemotherapy [43]. ONYX-015
(Onyx Pharmaceuticals) is a modified oncolytic adeno-
virus that was previously approved by the Chinese Food
and Drug Administration (2005) in the management of
refractory head and neck cancer in combination with
cisplatinum [16]. It is presently being investigated in
the management of other solid malignancies. Other
oncolytic adenoviruses include Ad5-D24, recombinant
H103, Ad5-CD/TKrep, CG7870, KH901, and OBP-301
(Telomelysin). The latest generation of adenoviral vectors
is the gutless adenovirus; it has an impressive safety pro-
file, less in vivo immune response and long-term sustained
gene expression [24]. Most clinical trials using oncolytic
adenoviruses rarely produce dramatic tumor response.
However, when combined with other modalities of cancer
therapy, good tumor regression has been reported [38,42].
Adeno-associated virus
This represents small, single-stranded DNA viruses, which
do not usually cause infection without co-infection of a
helper virus, such as adenovirus, or herpes simplex virus.
They have the advantage of broad host range, low level of
immune response, and longer gene expression. One ex-
ample is the Eukaryotic adeno-associated virus, which is a
chimeric virus vector containing parvovirus and adeno-
virus [44]. It is capable of transfecting mitotic and quies-
cent cells, lacks immunogenicity and pathogenicity in
humans, and integrates stably into the host DNA at a pre-
dictable location within a chromosome-19 in cell culture,
but not in mammalian cells.
Herpes simplex virus
This is a large, enveloped double-stranded DNA virus
(150 kb), naturally neurotropic (prefer nerve cells), that in-
fects humans particularly at the oral and genital mucosa,
but ultimately spreads to sensory nerves to replicate or be-
come dormant at the sensory ganglions. Viral reactivation
may lead to oral or genital ulcerations, skin rashes, or even
encephalitis. Up to 80% of the population are seropositive
to the virus [45,46]. With genetic engineering, a modified
oncolytic recombinant replication-selective herpes sim-
plex virus has been developed, and has exhibited several
advantages: it has broad tropism, potent in causing tumor
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(apart from nonessential genes), can evade the host im-
mune system; and in case of toxicities, several effective anti-
viral therapies are presently available to control viral
replication. Another advantage is its viral capability to carry
a large load of transgenes, such as a pro-drug-activating
gene thymidine kinase enzyme that enhances tumor lysis
when ganciclovir medication is subsequently administered
intravenously (suicide gene) [45]; therapeutic immuno-
modulatory transgenes that augment the antitumor immune
response (such as talimogene laherparepvec) (OncoVEX
GM-CSF) [47]; and antiangiogenic genes to suppress
tumor vasculature [48]. Presently, modified oncolytic her-
pes simplex viruses such as Talimogene laherparepvec
(TVEC) as well as others, are being tested in several clin-
ical trials either as a monotherapy, or in association with
surgery, radiation therapy or chemotherapy, particularly
on patients with high-grade glioma. Currently, some suc-
cess has been reported [45].Lentivirus vector
Lentiviruses are retroviruses that infect bovine, equine,
nonhuman primates and humans [49]. One of the most
destructive human pathogens is human immunodefi-
ciency virus infection (HIV). It constitutes a class of
enveloped viruses that contain a single-stranded 9.2 kb
RNA genome. The lentivirus carries a reverse tran-
scriptase enzyme that transcribes RNA into double-
stranded DNA once it enters the cytoplasm. It then
integrates permanently into the nuclear genome of the
target cells. Examples include lentiviral vectors derived
from immunodeficiency viruses such as HIV-1, HIV-2.
With genetic engineering, researchers have removed the
infectious parts of the virus and added other parts from
different viruses such as cytomegalovirus, generating a
highly modified lentivirus [50]. Another genetic modifi-
cation employed by previous researches created an
integration-deficient lentiviruses that did not integrate
into a host genome [51,52], though with slightly lower
transduction efficiency. Such a modified lentivirus has
the advantage of being relatively safe, of having variable
specificity to either a particular cell or is broad enough
to infect all cells, and of having efficient transduction of
both dividing and non-dividing cells. Modified viruses
have low antivirus immunity, low potential for genotoxi-
city due to insertional mutagenesis, and the capability of
carrying genes inside the nucleus [49]. Major disadvan-
tages include inadequate immune responses as well as
antitumor response, the risk of viral transformation into
pathogenic HIV infection, especially in immunized indi-
viduals, and insertional mutagenesis of new cancer
genes into the host genome, with the risk of second
malignancy [49].Reovirus
This is an oncolytic virus that usually infects animals. In
humans, it rarely causes major illness except for respiratory
and gastrointestinal symptoms. Nearly 100% of human
adults are seropositive to the virus [53]. It is non-
enveloped, double-stranded RNA (dsRNA), and its onco-
lytic activities are mainly through stimulation of the
immune system, particularly through bystander immune
activation. The release of tumor-associated antigens fol-
lowing cellular lysis further stimulates innate immunity
against tumor cells. The virus is considered relatively be-
nign, with good safety records, does not require genetic al-
terations to become an oncolytic virus, and is less
expensive to be produced commercially. Because of its
relative safety, the virus is presently being used in several
clinical trials, as oncolytic reovirus monotherapy, adminis-
tered intratumoral, intravenously, or intraperitoneally; or
as polytherapy, in combination with radiation therapy or
chemotherapy [53].
Gene therapy implementation
Once genetic materials are transferred into target cells
and incorporated into nuclear genetic DNA, they may
induce silencing, down-regulation, modification, or re-
pair of the target cell genes. Depending on the intensity of
the gene expression, it may lead to cell death and tumor
necrosis (as with the suicide gene), or impaired cell
growth with tumor regression (as with the silencing gene).
Modification of the gene may improve the response from
subsequent cancer therapy, such as chemotherapy, im-
munotherapy, or radiation. Repair of the target gene may
help in preventing subsequent malignancy or cancer-
related complications such as thrombosis. They may also
be helpful in the future by preventing hereditary cancer
syndromes.
Suicide gene
These are transgenes that make up products that can
cause a cell to kill itself through apoptosis. Such gene
products are usually transcribed by various factors (pro-
moters) leading to cell death and necrosis. One example
of such promoters is the human H19 RNA gene which is
highly expressed in most fetal organs but rapidly cleared
immediately after birth [54]. This gene has shown an ab-
normal expression in various types of cancer cells, and
plays an important role in cancer cell proliferation, genetic
instability, vascular angiogenesis, tumor metastases, multi-
drug resistance as well as cell survival despite hypoxia,
with secondary tumor progression and dissemination [55].
Blocking H19 gene function leads to marked tumor
regression, cellular death and necrosis. Another import-
ant promoter is human telomerase reverse transcriptase
(hTERT), which is a critical factor for cell immortalization
and tumorigenesis [56]. Its blockage with agents such as
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cell necrosis and tumor regression (Figure 1). Other ap-
proaches to induce tumor cell death include the use of
small-molecule drugs, monoclonal antibodies, and toxin
gene therapy with agents such as Corynebacterium diphther-
iae toxin-A chain (DTA-H19 therapy) [57].
Gene silencing
This has been achieved through specific delivery of a small
interfering double-stranded RNA (siRNA) into target cells,
and subsequent duplex formation of RNA-induced silencing
complex (RISC) that destroys messenger-RNA (mRNA),
thus leading to interference with RNA functions and pro-
tein synthesis within the target cells [58]. Through the ap-
propriate design of siRNA, it is theoretically possible to
use the technology in silencing any gene in the body, pro-
viding a greater therapeutic potential in cancer therapyFigure 1 Genetically-modified adenovirus acting as a suicide gene.
virus acting as a suicide gene, namely OBP-301 (Telomelysin) (Courtesy[59], as well as in the management of other medical disor-
ders such as the hepatitis B virus, human papilloma virus,
hypercholesterolemia and liver cirrhosis [59,60]. As siRNA
does not interact with chromosomal DNA, it does have a
lower risk of inducing target cell gene alterations and pos-
sible mutagenesis. It is highly specific against target genes,
with low systemic toxicities, and does not induce multi-
drug resistance. Furthermore, these genes can induce po-
tent gene silencing of many cancer-related genes, leading
to tumor regression, but do not abolish abnormal genes.
siRNA therapy can be administered directly into tumors;
however, for systemic administration, it is somewhat diffi-
cult as a naked siRNA protein is liable for host-mediated
clearance by enzymatic degradation, renal filtration, and
host cellular phagocytosis. Several delivery systems for
siRNA have been developed to protect them from enzym-
atic degradation, and facilitate their effect in silencingThe above mode of action represents an example of a modified
Oncolys BioPharma Company, Tokyo, Japan).
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system presently in clinical trials include CALAA-01
(Calando Pharmaceuticals) for patients with malignant
melanoma [61], and ALN-VSPOI (Alnylam Pharmaceuti-
cals) for liver cancer and solid tumors [62]. However,
limited success has been achieved mainly due to relatively
high toxicity and low transfection efficiency [58,59].
Gene modification
This may be helpful in improving cancer therapy results,
such as with radiation therapy. Radiosensitizing gene
therapy promotes transgene expression in tumor tissue,
thus increasing tumor sensitivity to radiation with better
tumor control [63-65]. In contrast, radioprotective gene
therapy distributes transgenes and their products to sur-
rounding normal tissue, thus limiting radiation induced
toxicities to normal tissue [66]. The concept of combin-
ing both approaches is presently being investigated in
several preclinical studies.
Gene repair
This can be achieved using zinc finger nuclease attached to
the lentiviral vector. Once the viral vector enters the nu-
cleus, it binds to a specific location in the double-stranded
DNA, breaking it at specific location, with subsequent en-
dogenous repair mechanisms, to create a newly edited
double-stranded DNA [23]. Other technological approaches
include transcription activator-like effector nucleases
(TALENs) [67,68], and clustered regularly interspaced
short palindromic repeats (CRISPR) [69].
Gene therapy for mitochondria
Gene therapy may also be directed to cytoplasmic organ-
elles such as mitochondria. The mammalian mitochon-
dria are responsible for metabolic functions. Nearly 300
of the known mutations causing metabolic diseases are
secondary to disorders affecting the mitochondrial gen-
ome [23]. Several approaches have been used to transfer
genes successfully into cell mitochondria.
Immunomodulation
It has become apparent that the immune system is a cru-
cial element in cancer regression or progression. There are
two types of immune responses: humoral immunity and
cellular immunity. Furthermore, the tumor microenvir-
onment plays an important role in host immune effects
against cancer cells [Table 1].
Humoral immunity is mediated by antibodies released
by B-cells with a high-binding affinity to specific tumor
antigens. The Food and Drug Administration in the
United States (FDA) approved several antibodies against
malignant cells, which include trastuzumab for breast can-
cer [70], rituximab for indolent lymphoma [71], cetuximabfor lung cancer [72], and bevacizumab for various solid tu-
mors [49,73], and many others [74] [Table 2].
Cellular immunity is mediated by cell-to-cell contact
that leads to antigen recognition and cell destruction of
a target cell. Based on the intensity of tumor-associated
antigens (TAAs) on the surface of tumor cells, they are
recognized by the host immune system [75]. Dendritic
cells are specialized in antigen recognition as well as me-
diation of immune responses against infectious agents or
malignant cells, through direct stimulation or inhibition of
immune effector cells such as T-cells, B-cells, and natural
killer (NK) cells [76]. Dendritic cells are derived from the
bone marrow and migrate to lymph nodes and distant
tissue, looking for those foreign antigens [49].
Cancer cells can evade the immune system by secret-
ing immunosuppressive cytokines that can downregulate
major histocompatibility molecules, can recruit regulatory
T-cells, and can kill reactive cytotoxic lymphocytes. Thus,
the tumor microenvironment is highly immunosuppres-
sive, which allows a tumor to grow and metastasize [77].
Several efforts have been undertaken to manipulate
the tumor microenvironment in order to induce tumor
regression.
Innate immunity
Most tumor cells express antigens that can mediate
antitumor immune responses [78]. Earlier studies on
antigens for therapeutic targeting were based on shared
antigens that are expressed on self-tissue or peripheral
cells, which can lead to immunologic tolerance for the
interaction between antigen peptide, major histocom-
patibility complex (MHC), and T-cell antigen receptor
(TCR). Generated immunologic responses were res-
tricted with low therapeutic efficacy [78]. Recently, it
has been found that neoantigens generated by point
mutation in normal genes, which are unique to particu-
lar tumors, can result in much more potent antitumor
T-cell response. Some cancers display hundreds or even
thousands of mutations in coding exons, representing a
large resource of potential targets for recognition by the
immune system. However, despite such a plethora of
antigens, most cancers progress and evade immune-
system mediated destruction [78].
Antigens recognition by dendritic cells induce a T-cell in-
flamed reaction consisting of infiltrating T-cells, a broad
chemokine profile, and type I interferon signature indicative
of innate immune activation. Presence of excessive infiltra-
tion by CD8+ cells both within the tumor and in the peritu-
moral stroma (high immunoscore) had a favorable
prognostic significance with improved survival, even in ad-
vanced cancer stages, compared to tumors with poor or no
T-cell infiltration (low immunoscore) at an earlier stage of
malignancy [79-81]. Hence, a heavy presence of activated
CD8+ T-cells reflects good innate immune responses
Table 2 Monoclonal antibodies in cancer management
Name Class Target Approved initial indications FDA Approved
Rituximab (Rituxan) Chimeric IgG1 CD20 Non-Hodgkin lymphoma 1997
Trastuzumab (Herceptin) Humanized IgG1 HER2 Breast cancer 1998
Alemtuzumab (Campath) Humanized IgG1 CD52 B-cell CLL 2001
Ibritumomab tiuxetan (Zevalin) Murine IgG1 CD20 Non-Hodgkin lymphoma 2002
Tositumomab (Bexxar) Murine IgG2a CD20 Non-Hodgkin lymphoma 2003
Cetuximab (Erbitux) Chimeric IgG1 EGFR Squamous cancer head & neck 2004
Bevacizumab (Avastin) Humanized IgG1 VEGF Colorectal cancer 2004
Panitumumab (Vectibix) Humanized IgG2 EGFR Colorectal cancer 2006
Ofatumumab (Arzerra) Humanized IgG1 CD20 CLL 2009
Denosumab (Xgeva) Humanized IgG2 RANKL Bone metastases 2010
Ipilimumab (Yervoy) Humanized IgG1 CTLA-4 Metastatic melanoma 2011
Brentuximab vedotin (Adcetris) Chimeric IgG1 CD30 Hodgkin lymphoma 2011
Pertuzumab (Perjeta) Humanized IgG1 HER2 Breast cancer 2012
Trastuzumab emtansine (Kadcyla) Humanized IgG1 HER2 Breast cancer 2013
Obinutzumab (Gazyva) Humanized IgG1 CD20 B-cell CLL 2013
Name Class Target Present indications Clinical Trials**
Amatuximab Chimeric IgG1 mesothelin mesothelioma Phase-I
Elotuzumab Humanized IgG1 CS1 Multiple myeloma Phase-III
Farletuzumab Humanized IgG1 FRA Ovarian and lung cancers Phase-III
Inotuzumab ozogamicin Humanized IgG4 CD22 ALL, Malignant lymphoma D/C
Moxetumomab pasudotox Murine Fv-CD22 CD22 Hairy cell Leukemia Phase-III
Naptumomab estafenatox Murine Fab 5 T4 Renal and solid malignancies Phase-II
Necitumumab Humanized IgG1 EGFR NSCL (Squamous cell) Phase-III
Nivolumab Humanized IgG4 PDI NSCL, Melanoma, Renal Phase-III
Ontuximab Humanized IgG1 TEM1 Solid tumors Phase-I/II
Onartuzumab Humanized IgG1 c-Met NSCL, Gastric D/C
Racotumomab vaccine (Vaxira) Murine GM3 NSCL Phase-III
Rilotumumab Humanized IgG2 HGF/SF Gastric, GEJ Phase-III
Abbreviations: 5 T4 Antigen expressed on several solid tumors; ALL acute lymphocytic leukemia; c-MET MNNG HOS proto-oncogene that encodes hepatocyte
growth factor receptor; CLL chronic lymphocytic leukemia; CTLA-4 cytotoxic T lymphocyte inhibitors mediated by malignant cells; CS1 human CS1 antigen
glycoprotein belonging to CD2 subset of the immunoglobulin superfamily; D/C clinical trials that were discontinued due to the lack of efficacy or excessive
toxicities; EGFR, epidermal growth factor receptor; FDA Food and Drug Administration in United States; FRA folate receptor alpha; GM3 tumor antigen N-glycolil,
a type of ganglioside present on the surface of breast and lung cancer cells; HGF human hepatocyte growth factor receptors; Mesothelin mesothelin is cell surface
glycoprotein overexpressed in multiple malignancies such as mesothelioma; NSCL non-small cell lung cancer; PD-1 human cell surface receptor programed
death-1, results in activation of T cell mediated immune responses; RANKL RANK ligand protein that acts as the primary signal for bone removal, loss, or
destruction; TEM1 tumor endothelial Marker-1 and CD248 (Morphotek Inc, Exton, PA); VEGF vascular endothelial growth factor receptor.
**Active clinical trials on monoclonal antibodies in cancer management as of July 1st, 2014 (www.clinicaltrials.gov).
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gested two explanations for tumor escape recognition by
host immune system, based primarily on cellular and mo-
lecular characteristics of the tumor microenvironment [78].
One explanation is that tumors resist immune attacks
through inhibitory effects mediated by immune system
suppressive pathways. This was evident in some tumors
such as melanoma with high expression of PD-LI and
indoleamine-2,3-dioxygenase (IDO) [82], leading to T-cell
anergy and dysfunction with subsequent immune escapedetection [83]. The presence of transcription factor fork-
head box 03 proteins (Fox3) in the peritumoral micro-
environment leads to the inhibition of tumor-infiltrating
dendritic cell stimulatory functions [84]. The US FDA’s
approval in 2011 of the anti-CTLA-4 monoclonal anti-
body ipilimumab for the treatment of patients with
advanced malignant melanoma [85] represents the first-
in-class strategy of uncoupling inhibitory pathways for ini-
tial antigen recognition by the host immune system [78]
[Figures 2 and 3].
Figure 2 Mechanism of action of monoclonal antibody ipilimumab. Generation of an immune signal requires presentation of tumor antigen by
major histocompatibility complex (MHC) class I or II molecules, on an antigen presenting cell (APC) such as dendritic cell. However, T-cell activation
and proliferation requires a second signal, typically generated by CD28 antigen. When CD28 antigen on T-cell surface simultaneously binds to
costimulatory B7-1/B7- ligand on the antigen presenting cell (APC), T-cell upregulate and translocate CTLA-4 receptor molecules to the surface, which
binds B7 with a higher avidity than CD28, leading to suppressor effects, with T-cell inhibition, reduction of interleukin-2 (IL-2) secretion, and prevention
of immune response against malignant cell. Ipilimumab blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4) receptor, thus prevents such inhibitory
effect, and allows T-cell to proliferate and mediate an immune reaction against malignant cells. Other regulatory checkpoints with the potential for
modulation include the coinhibitory molecule PD-1, as well as costimulatory molecules such as OX40 and 4-1BB. Abbreviations: APC, antigen
presenting cells; CTLA-4, cytotoxic T-lymphocyte antigen-4; MHC, major histocompatibility antigen; TCR, T-cell receptor. (Courtesy of Annals of New
York Academy of Science and Wiley, Hoboken, New Jersey, Publisher) [86].
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Figure 3 Analysis of overall survival comparing monoclonal antibody ipilimumab plus dacarbazine to placebo plus dacarbazine in
metastatic melanoma patients. Kaplan–Meier analysis of overall survival in the phase III study CA184-024. Survival analysis of overall survival in
treatment-naive patients with advanced melanoma who received ipilimumab at 10 mg/kg plus DTIC or placebo plus DTIC in the phase III trial,
CA184-024. The survival curves reach a plateau beginning at approximately three years after initiation of treatment. Continued survival follow-up
of more than four years demonstrates a long-term survival benefit that is consistent with the results of other ipilimumab studies. Abbreviations:
DTIC, dacarbazine; Ipi, ipilimumab, Plac, placebo (Courtesy of Annals of New York Academy of Science and Wiley, Hoboken, New Jersey, Publisher) [86].
Amer Molecular and Cellular Therapies 2014, 2:27 Page 11 of 19
http://www.molcelltherapies.com/content/2/1/27The other mechanism is immune system exclusion or
ignorance with subsequent poor or no T-cell inflamma-
tory reaction. Such tumors appear to lack a type I
interferon signature and/or chemokines for recruitment
of T-cells. Microenvironment vasculature may be nonper-
missive for entry by T-cells, and the stromal element
may prevent trafficking and/or function of T-cells. Radia-
tions of tumors have shown to induce productions of
interferon-beta and augment function of intratumoral
dendritic cells with improved accumulation of T-cells
leading to tumor regression [87]. Imatinib in gastrointes-
tinal stromal cell tumors may cause down-modulation of
IDO with improved antitumor response [88]. In patients
with malignant melanoma, inhibition of R-Raf enzyme
activity with vemurafenib can induce a T-cell infiltration
within 1–2 weeks of therapy with some tumor responses
[89]. It has been suggested that combination regimens
consisting of strategies to improve innate immune system
activation, T-cell trafficking in the tumor microenviron-
ment, vaccination or adoptive T-cell transfer, and block-
age of immune inhibitory pathways may be necessary to
achieve clinical benefit in patients with a non-inflamed
tumor phenotype. Such an approach is presently being
tested in clinical trials [90,91].Immunomodulatory approaches in cancer therapy
Immunotherapy in cancer can be classified into four
major categories [92]. Active immunotherapy includes
strategies that directly sensitize the host immune system to
tumor-specific antigens, exemplified as cancer vaccines.
Passive immunotherapy utilizes humanized or chimeric
antibodies to specifically target tumor antigens without dir-
ect activation of the immune system. Adoptive immuno-
therapy utilizes patients’ immune cells, whether T-cells or
dendritic cells, stimulated or manipulated ex vivo, then in-
fused back, to better react against tumor antigens. Immune
enhancement therapy aims to augment co-stimulatory
molecules or block inhibitory molecules. Immune-based
therapy may include one or more of the above approaches,
either as distinct immunotherapy treatment, or in combin-
ation with other modalities of cancer therapy [Table 1].
Autologous stimulated T-lymphocytes
Adoptive T-cell therapy has been shown to induce tumor
regression in some patients with solid malignancies.
In a recent study on patients with human papilloma
virus (HPV)-induced metastatic cervical cancer who
failed to respond to chemotherapy and radiation, and were
selected for HPV-E6 and HPV-E7 reactivity, researchers
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infused them back to patients. This was preceded by a
non-myeloablative conditioning regimen and followed
by a high-dose of bolus aldesleukin (interleukin-2).
Three out of six patients with HPV reactivity achieved
objective tumor responses, including two patients with
metastatic disease that achieved complete tumor regres-
sion for 18 and 11 months after therapy. Side effects were
minimal [93].
Autologous activated T-lymphocytes
Host T-cell lymphocytes have been found to be successful
in controlling metastatic cancer with transient side ef-
fects. The first commercially available vaccine was modi-
fied dendritic cells, sipuleucel-T (Provenge) (Dendron
Corporation), which was approved by the FDA for minim-
ally symptomatic castration-resistant metastatic prostate
cancer. CD54 T-cell lymphocytes were obtained from the
patients using density gradient centrifugation, and then
activated ex vivo with a prostatic specific antigen in
addition to granulocyte macrophage colony stimulating
factor (GM-CSF) to form sipuleucel-T. Autologous acti-
vated T-cell lymphocytes, at a dose of at least fifty million
CD54 cells were infused back to the patient, intravenously
over 60 minutes, every two weeks for three infusions. Pre-
medications included acetaminophen and diphenhydra-
mine. Side effects included transient fever, chills, fatigue,
asthenia, backaches, and headaches. However, infusion-
induced hypersensitivity reactions with cerebrovascular
events have been reported in 3.5% of patients. Compared
to a control group treated with a placebo, there were sig-
nificant improvements in the survival of 20.5% versus
16.1% at four years [94].
Genetically modified activated T-lymphocytes
The adoptive transfer of lymphokine-activated lym-
phocytes can mediate the cellular immune response
against cancer cells, which may lead to tumor regres-
sion. However, clinical trials have led to limited suc-
cess. An alternative approach is to use genetically
modified T-cells by altering their receptor for better
recognition of tumor antigens. In such an approach,
T-cells are collected from patient apheresis using
density gradient centrifugation. As resting T-cell lym-
phocytes are non-dividing, refractory to gene therapy
with lentiviral vectors, they need to be stimulated
using cytokines such as interleukin-2. T-cells are then
exposed to lentiviral vectors with the attached gene
for 1–2 days of gene transfer. After transduction by
the lentivirus, cells are then stimulated further to ob-
tain a therapeutically effective number of cells. Genet-
ically modified T-cell lymphocytes are then re-infused
back into the patient [95]. The high-affinity of modi-
fied T-cells in detecting very low levels of tumorantigens is an extremely potent approach against
tumor cells. However, it may also destroy normal cells.
In another study using T-cell receptor gene-modified cells
against melanoma differentiated antigens led to higher
responses in patients with malignant melanoma [96]. It
also destroyed normal melanocytes leading to vitiligo (skin
depigmentation), uveitis, and hearing impairment [97].Chimeric antigen receptor integrated into T-lymphocytes
Elimination of malignant cells through host immune sys-
tem depends largely on α β T-cell receptor that specific-
ally recognize a cell target in the context of the major
histocompatibility complex (MHC). Unfortunately, for
many B-lineage leukemias and lymphomas, the resident
immune system of patients remains incapable of control-
ling tumor growth, since autologous T-cells lack expres-
sion of the required receptors and tumor cells have
adapted to evade immunological recognition [98]. It has
been demonstrated that a chimeric antigen receptor
(CAR) integrated into T-cells from patient (or even from
healthy individuals), can directly recognize the CD19
molecule expressed on the cell surface of B-cell malignan-
cies independent of major histocompatibility complex
[99]. Recently, CD19-specific chimeric antigen recep-
tor redirected T-lymphocytes have been utilized as
gene therapy for patients with B-cell malignancies.
One approach is to use a microelectroporator to
achieve high throughput non-viral gene transfer of
naked DNA plasmid, of in vitro transcribed CAR
mRNA into human T cells that had been numerically
expanded ex vivo using interleukin-2. After electropor-
ation, a procedure that usually takes about 10 minutes, up
to 80% of the passaged T-cells expressed the CD19-
specific CAR, with redirected effector function of the gen-
etically manipulated T-cells to specifically lyse CD19+
tumor cells. Preserved T-cells can then be re-infused into
patient as an effector form of adoptive immunotherapy
[98] [Figure 4]. Similar approaches have been used against
other B-lineage restricted antigens such as CD20 in
lymphoma, the light chain of human immunoglobulins, or
CD30 expressed by Reed-Sternberg Cells in Hodgkin
lymphoma [100]. Adding costimulatory endodomain
within the chimeric receptors such as CD28, 4-1BB, or
their combination, usually leads to enhancement of T-
cell functions through the release of interleukin-2,
interleukin-7 or interleukin-15 cytokines [100]. Excellent
results in patients with B-cell malignancies have been re-
ported [101-103]. CAR-modified allogeneic T-cells, such
as those obtained from healthy individuals, have the
potential to act as universal effector cells, which can be
administered to any patient regardless of MHC type. Such
universal effector cells could be used as an 'off-the-shelf'
cell-mediated treatment for cancer [104,105].
Figure 4 Chimeric antigen receptor modified T-lymphocyte therapy for B-cell malignancies. Generation of tumor-specific T cells by
repeated antigen stimulation or genetic modification to express a tumor-targeting receptor. PBMC collected from a patient or healthy individual
can be stimulated in vitro with tumor antigen at regular intervals to induce gradual enrichment of antigen-specific T cells (blue). Multiple
stimulations followed by additional enrichment or expansion strategies are required to ensure sufficient antigen-specific T cells are generated.
The entire process may take 2–3 months. In contrast, approaches that utilize genetic modification to redirect T cell specificity to a tumor antigen
are much more rapid. PBMC can be collected from a patient or healthy donor and retrovirally or lentivirally transduced to express a tumor-reactive
CAR (or TCR). The enriched CAR-modified tumor-reactive T cells (red) can be infused into the patient in as little as 1–2 weeks. Abbreviations: PBMC:
Peripheral blood mononuclear cells, CAR: Chimeric antigen receptor modified T-lymphocytes. (Courtesy of The International Journal of Hematology,
and Springer-Tokyo, Publisher) [102].
Amer Molecular and Cellular Therapies 2014, 2:27 Page 13 of 19
http://www.molcelltherapies.com/content/2/1/27Genetically modified dendritic cells
Dendritic cells are the most powerful antigen-presenting
cells (APCs) for antigen identification, T-cell costimulation
and cytokine production by T lymphocytes [106]. Dendritic
cells can be generated from monocytes or a CD34+ cell
precursor [107], and can be harvested from peripheral
blood using density gradient centrifugation. When cultured
in the presence of granulocyte-macrophage colony-
stimulating factor (GM-CSF) plus interleukin-4, monocytes
develop into immature dendritic cells in 3–5 days. Cells are
then exposed to a variety of different stimuli over another
2 days in culture media to become mature dendritic cells,
which are more effective in stimulating T-cells [108]. To
target a specific tumor, mature dendritic cells are incubated
with certain peptides, proteins, or irradiated tumor cells.
An alternative approach is genetic modification of dendritic
cells through viral and non-viral gene transfer vectors,
resulting in dendritic cells that are more potent in antitu-
mor immunity. Dendritic cell vaccines have a favorable
safety profile, with toxicities limited to a local inflammatory
reaction, flu-like symptoms, and vitiligo-like skin changes
[109]. Despite numerous clinical trials, clinical outcomes
have been modest. Emphasis has been shifted in using ther-
apy on patients with a lower tumor burden, such as those
after surgery, or following successful chemotherapy or radi-
ation therapy. Indeed, significant synergy has been observed
for chemotherapy and dendritic cell vaccines [107].Genetically modified tumor cell vaccine
Previous attempts to use tumor cells or their products as a
vaccine have not been successful. Subsequently, clinical trials
have been conducted using methods to increase tumor anti-
genicity in order to enhance the immune-mediated tumor
lysis by T-cells. One approach is to obtain tumor cells, infect
them with a viral vector such as recombinant poxvirus that
contains multiple costimulatory molecules to enhance the
immunogenicity of tumor cells, and subsequently use those
modified tumor cells as a vaccine. An alternative approach
is to directly administer the poxviral vector into the tumor.
Such an approach enhances tumor antigenicity and subse-
quent antigen-specific T-cell response, leading to an antitu-
mor effect. Other viral vectors include vaccinia virus and
recombinant nonreplicating fowlpox virus encoding GM-
CSF (TRICOM) [110]. This has led to the development of
the Prostvac-VF vaccine (Bavarian Nordic, Inc.) which
employs a recombinant vaccinia vector as a primary vaccin-
ation, followed by multiple booster vaccinations employing
a recombinant fowlpox vector. Both vectors contain the
transgenes for prostate-specific antigen (PSA) and multiple
T-cell costimulatory molecules (TRICOM). In a randomized
clinical study, using the vaccine versus placebo, in 125 pa-
tients with metastatic castration resistant prostate cancer,
there was an improved survival at 3 years of 30% for the
vaccinated group compared to 17% for the placebo patients
[18]. A Phase-III clinical trial is presently in progress.
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DNA plasmids containing a genetic sequence that encodes
a desired antigen with other transcriptional elements have
been considered as a mode of cancer vaccine. It readily ac-
cesses the nucleus of a transfected cell, transcribed into a
peptide or protein, and may lead to cellular and humoral
immune response [111]. The technique is considered to
be relatively safe compared to viral or bacterial vectors,
does not cause infection or autoimmune disorders, and is
easy to develop and produce commercially [112]. How-
ever, its effectiveness wanes with time. Hence, the need
for frequent booster immunizations. Examples of single-
antigen plasmid-based vaccines include human prostatic
acid phosphatase protein for patients with prostate cancer
[113], human epidermal growth factor receptor-2 (HER-2/
neu), protooncogene with low-doses of GM-CSF intrader-
mally for patients with metastatic breast cancer [114], and
modified carcinoembryonic antigen (CEA) gene fused to a
promiscuous tetanus toxoid for colorectal cancer [115].
Although therapy was well tolerated, responses were min-
imal and transient. Using a multiple-antigens plasmid-
based vaccine leads to broadly specific, long lasting, and
multifunctional immune stimulation [116]. Improved re-
sults were noticed [117,118].
Genetically modified microenvironment
The microenvironment around a tumor plays an import-
ant role in tumor progression and metastases. It includes
stromal tissue, fibroblasts, and vascular endothelial cells.
Interfering with such a microenvironment will lead to
tumor regression. The most important target is angiogen-
esis, which is essential for tumor growth and metastases.
It is mediated by tumor-derived pro-angiogenic cytokines,
such as the vascular endothelial growth factor and fibro-
blast growth factor. These factors stimulate the prolifera-
tion of microvasculature around a tumor, with subsequent
tumor progression and metastases. Compared to the
recombinant antivascular endothelial factor antibody
“bevacizumab”, gene therapy represents an attractive
alternative to such drug therapy. Using an anti-angiogenic
genes, such as angiostatin and endostatin, delivered by an
adeno-associated virus vector, has led to tumor regression
with minimal side effects [24].
Other gene therapy approaches in cancer
management
As with other modes of cancer therapies, multimodality
treatment frequently yields, better results compared to
monotherapy. This is similarly true for gene therapy, and
is evident when gene therapy is administered after max-
imum tumor load reduction following radical surgery or
successful chemotherapy. Gene therapy has a synergistic
effect when combined with chemotherapy, with higher
tumor responses and lower therapy-related toxicities.Gene directed enzyme prodrug therapy (GDEPT)
This is a new strategy in cancer management that aims to
reduce the side effects of chemotherapy. With such an ap-
proach, a gene that expresses a nontoxic enzyme into can-
cer cells is first delivered to the cells, followed by the
systemic administration of a pro-drug that can be con-
verted into a toxic compound by the enzyme, leading to se-
lective tumor cell death, with lower adverse effects on
normal tissues [119]. Cell-to-cell diffusion of toxic metabo-
lites may damage nearby and adjacent tumor cells (by-
stander effect) [120]. Release of tumor cell necrotic
material in the circulation may activate the immune system
in response to the tumor antigen, with subsequent regres-
sion of distant tumor cells, such as metastatic nodules (dis-
tant bystander effect) [121]. Examples include the use of a
retroviral vector, such as suicide gene therapy and herpes
simplex virus carrying the thymidine kinase enzyme, to the
interior of tumor cells. The enzyme has a 1000-fold greater
efficiency to selectively phosphorylate the acyclovir-derived
pro-drug ganciclovir [120]. Following the systemic admin-
istration of ganciclovir, the drug is metabolized in tumor
cells leading to cell death. As the efficacy of such a system
is only about 10% of tumor cells, the extent of tumor re-
gression is mainly mediated via bystander effects. The sys-
tem has been tried in several clinical trials [122]. Replacing
ganciclovir with a penciclovir drug, modified to gen-
erate radiolabeled analog, will also allow a closer
follow-up of therapy results, using high-quality positron
emission tomography imaging studies [123].
Cancer drug-resistance gene transfer
Several studies have used a gene transfer approach that
aims to enhance chemotherapy and radiation effects against
cancer cells, while protecting normal tissue against therapy
mediated toxicities. Such gene transfer may also be used
in the protection against HIV virus by making normal
cells resistant to viral invasion, or correction of genetic
disorders such as sickle cell anemia or metabolic disor-
ders. However, incorporating a new gene into a host stem
cell’s genome, for the life of an individual, may promote
other oncogenes to develop malignant disorders, and may
change other adjacent genes, thus creating other medical
diseases. Hence, it is a risky approach in gene therapy.
Few clinical trials have recently been conducted in this
regards. One example is the multidrug-resistant protein-1,
which is encoded by the human ABCBI gene named as
MDR1 gene. It stimulates the cellular pump to remove
cytotoxic drugs from normal cell cytoplasm to the outside,
thus protecting normal cells from chemotherapy’s side
effects, such as with vinca alkaloids, taxanes, epipodo-
phyllotoxins and anthracyclines [124]. The MDR1 gene is
minimally expressed in malignant cells; thus, chemothera-
peutic medications entering the cytoplasm will remain
at a higher concentration, leading to cell death. Other
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ferase (MGMT) for alkylating chemotherapy [125,126],
and glutathione transferase (GSTP1) for cisplatin, doxo-
rubicin, and cyclophosphamide [127,128,124].
Theranostic approach
In a combined diagnostic and therapeutic system (theranos-
tic), gene therapy may also be combined with other diag-
nostic measures to help diagnose, treat and monitor the
response to therapy. For example, a small interfering
double-stranded RNA (siRNA) delivery system can be la-
belled with imaging agents such as dextran-coated super-
paramagnetic nanoparticles for simultaneous noninvasive
imaging of siRNA delivery to tumors, using magnetic res-
onance imaging (MRI) [59]. The siRNA delivery system can
also be labeled with other imaging agents to closely moni-
tor therapy, and may even predict the outcome of therapy
long before any anatomical changes [129]. Such molecular
diagnostic approaches have been evolving relatively fast in
the last few years, and may become an important avenue in
cancer diagnosis sometime in the near future [59].
Problems with gene therapy
The most frequent side effects following gene therapy in-
clude transient fever and flu-like symptoms [24]. A grade-3
hypersensitivity reaction following intravenous administra-
tion is usually transient and managed with the usual sup-
portive measures. Leukocytopenia, and in particular,
lymphopenia, may represent cellular redistribution of white
blood cells to target tissue such as tumors. Mild transient
anemia has also been reported [130]. However, toxicity,
mutagenicity and immunogenicity associated with viral vec-
tor therapy have raised great concern [12].
Retroviral (such as lentiviruses) mediated gene therapy
leads to viral integration into host genome, thus, it may
cause mutagenic events with possible second malignancies.
This was reported in earlier studies on the murine leukemia
retrovirus vector in the treatment of patients with severe
combined immunodeficiency and five out of 30 cases devel-
oped leukemia [131], though, no second malignancy has
been reported so far, in gene therapy for cancer. Such mu-
tagenicity depends on the site of viral insertion. For this
reason, the FDA has required all clinical trials involving
genomic integrated viral vectors to report and analyzes viral
vector insertion sites. Initial methodology was linear ampli-
fication mediated polymerase chain reaction [132], but
lately, high-throughput DNA sequencing methods have
been used [133,134]. Clinical trials that initially or subse-
quently show evidence of higher mutagenicity are usually
discontinued. Information obtained from such studies is of
major significance in designing new and much safer thera-
peutic approaches [58].
Another major problem with gene therapy for cancer
is the resistance to treatment with subsequent tumorrecurrences and shorter survival. A potential mechanism
is intrinsic, and possibly acquired, tumor cell resistance
to therapy-induced cell death (apoptosis) by dysregula-
tion and release of anti-apoptotic inhibitor of apoptosis
protein or Bcl-2 proteins [24]. Recently, some pharma-
ceutical companies have developed several medications
such as Novartis-LBH589, cIAP1, and cIAP2 which inhibit
the Bcl-2 protein, thus promoting cell death (apoptosis)
and tumor regression, prevent or delay tumor resistance,
and prolong remission following gene therapy. These med-
ications are presently in clinical trials [24,135].Review, Conclusions
Gene therapy for cancer has evolved relatively fast in the
last two decades, and presently, few drugs are commer-
cially available while others are still in clinical trials.
Most reports on gene therapy have shown good safety
profiles with transient tolerable toxicities. The lack of
success in several clinical trials may partly be attributed
to patient selection. Similar to initial chemotherapy out-
comes thirty years ago, patients with advanced and
therapy-resistant malignancies are presently enrolled in
gene therapy trials. Perhaps, gene therapy maybe much
more successful in patients with earlier stages of malignan-
cies, or in those who have a lower tumor burden. Alterna-
tively, gene therapy may better be used after successful
cancer therapy with maximum tumor load reduction, such
as after radical surgery, following radiation therapy, or after
successful chemotherapy.
In the future, the wide use of patient and tumor gen-
omic analysis as well as the assessment of host
humoral and cellular immunity, will facilitate a better
selection of the most appropriate gene therapy per pa-
tient. Recent progress in developing safe and effective
vectors for gene transfer, such as with synthetic viruses
and non-viral methods, as well as the success in using
autologous and allogenic chimeric antigen receptor inte-
grated T-lymphocytes, even from healthy individuals, as
universal effector cells in mediating adoptive immunother-
apy, will increase the effectiveness and safety profile of
gene therapy. Furthermore, with the advancement in bio-
logical research, much cheaper gene vectors will become
commercially available, which will make gene therapy
readily available to the majority of cancer patients, world-
wide. This will transform the future of cancer therapy,
from generalized cancer treatment strategies, based on
tumor size, nature and location, to a more tailored, indi-
vidualized cancer therapy, based on the patient’s specific
genomic constituents, host immune status, and genetic
profile of the underlying malignancy. Treatment is
expected to be fast, effective, relatively less toxic and inex-
pensive, with higher cure rates, and may even, cancer
prevention.
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